273 related articles for article (PubMed ID: 22104158)
1. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
3. [Revenue and losses with vertebral augmentation under the G-DRG system 2012 - a comparison of supply costs in the context of vertebroplasty and kyphoplasty].
Krüger A; Wollny M; Oberkircher L; Bornemann R; Pflugmacher R
Z Orthop Unfall; 2012 Oct; 150(5):539-46. PubMed ID: 23076753
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Revenue Situation in Interventional Radiology Based on the Example of Peripheral Artery Disease in the Case of a DRG Payment System and Various Internal Treatment Charges.
Vogt FM; Hunold P; Haegele J; Stahlberg E; Barkhausen J; Goltz JP
Rofo; 2018 Apr; 190(4):348-358. PubMed ID: 29495050
[TBL] [Abstract][Full Text] [Related]
5. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
Stäbler W; Wagner B
Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
9. [Economic burden of Clostridium difficile enterocolitis in German hospitals based on routine DRG data].
Grube RF; Heinlein W; Scheffer H; Rathmayer M; Schepp W; Lohse AW; Stallmach A; Wilke MH; Lerch MM;
Z Gastroenterol; 2015 May; 53(5):391-7. PubMed ID: 25965986
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
Görner M; Riemer-Hommel P
Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
[TBL] [Abstract][Full Text] [Related]
14. Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstruction.
Jacobs VR; Rasche L; Harbeck N; Warm M; Mallmann P
Onkologie; 2010; 33(11):584-8. PubMed ID: 20975304
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
Morris PG; Bach PB
Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
[No Abstract] [Full Text] [Related]
16. [Primary hip- and knee arthroplasty--comparison of the actual costs with the Australian diagnosis related groups (DRG)-].
Schürmann N; Müller RT
Z Orthop Ihre Grenzgeb; 2002; 140(6):589-94. PubMed ID: 12476379
[TBL] [Abstract][Full Text] [Related]
17. An economic analysis of aseptic revision hip arthroplasty: calculation of partial hospital costs in relation to reimbursement.
Assmann G; Kasch R; Hofer A; Schulz AP; Kayser R; Lahm A; Merk H; Flessa S
Arch Orthop Trauma Surg; 2014 Mar; 134(3):413-20. PubMed ID: 24477287
[TBL] [Abstract][Full Text] [Related]
18. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
19. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
20. Cost comparison of capecitabine in patients with breast cancer.
Rugo HS; Kohles J; Schulman KL
Am J Clin Oncol; 2010 Dec; 33(6):550-6. PubMed ID: 20051811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
